Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 330, Issue 1-2, 1995, Pages 115-181

  Anderson, Diana ^a   Bishop, Jack B ^b   Garner, R Colin ^c   Ostrosky Wegman, Patricia ^d   Selby, Paul B ^e  

^a BIBRA INTERNATIONAL   (United Kingdom)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c The Jack Birch Unit for Environmental Carcinogenesis University Road Baslington York YO1 5DU UK ^*  (United Kingdom)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^e OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Cyclophosphamide; Cyclophosphamide mutagenicity; Germ cell effect

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; CHROMOSOME ABERRATION; DRUG METABOLISM; GENE MUTATION; GENETIC RISK; GENOTOXICITY; GERM CELL; HUMAN; METABOLIC ACTIVATION; MICRONUCLEUS; MUTAGENICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

ANIMAL; CHROMOSOME ABERRATIONS; CYCLOPHOSPHAMIDE; DNA ADDUCTS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERM-LINE MUTATION; HUMAN; MALE; MICE; MUTAGENICITY TESTS; MUTAGENS; OCCUPATIONAL EXPOSURE; RATS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SISTER CHROMATID EXCHANGE; SPECIES SPECIFICITY; SPERMATOZOA;

EID: 0029154091     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/0027-5107(95)00039-L     Document Type: Review

References (313)

1. Induction by indirect mutagens/carcinogens, aryl hydrocarbon hydroxylase activity and benzo[a]pyrene metabolism in cultured human hepatoma cells
2. Activation of cyclophosphamide using perfused rat liver system and induction of sister chromatid exchanges in vitro
3. ICPEM Working Paper 4/3: Comparison of types of chemically induced genetic changes in mammals
4. Mammalian male germ cell cytogenetics
5. Induction and transmission of chemically induced chromosome aberrations in female germ cells
6. Reevaluation of the 9 compounds reported conclusive positive in yeast Saccharomyces cerevisiae aneuploidy test systems by the Gene-Tox program using strain D61.M of Saccharomyces cerevisiae
7. Bladder cancer in a young girl with systemic lupus erythematous treated with cyclophosphamide
8. In vivo BrdU-33258 Hoechst analysis of DNA replication kinetics and sister chromatid exchange formation in mouse somatic and meiotic cells
9. Synaptonemal complex damage as a measure of chemical mutagen effects on mammalian germ cells
10. Synaptonemal complex damage as a measure of genotoxicity at meiosis
11. Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study
12. Vinyl chloride: dominant lethal studies in male CD-1 mice
13. Testing of ethylene oxide for mutagenicity using the micronucleus test in mice and rats
14. Chromosome damage in murine and human cells following cytoxan therapy
15. The uptake and metabolism of cyclophosphamide by the ovary
16. Short-term cytogenetic assays of nine cancer chemotherapeutic drugs with metabolic activation
17. 0 male rat: physical and behavorial changes in three successive adult generations
18. Synaptonemal complex damage in relation to meiotic chromosome aberrations after exposure of male mice to cyclophosphamide
19. Clinical pharmacology of cyclophosphamide
20. In vivo cytogenetic screening for determination of the mutagenic potential of cyclophosphamide
21. Genotoxicity studies with the unstable zeste-white (UZ) system of Drosophila melanogaster: results with ten carcinogenic compounds
22. Expression of genetic damage induced by alkylating agents in germ cells of female mice
23. Detection of micronuclei after exposure to mitomycin C, cyclophosphamide and diethylnitrosamine by the in vivo micronucleus test in mouse splenocytes
24. Genetic effects
25. Genetic effects of radiation
26. Cyclophosphamide-induced oncogenic transformation, chromosomal breakage, and sister chromatid exchange following microsomal activation
27. N-(2-major hydroxyethyl)-N-[2-(7-guaninyl)ethyl]amine, the putative DNA adduct of cyclophosphamide in vitro and in vivo in the rat
28. Activity of germ-cell mutagens and nonmutagens in the rat spermatocyte UDS assay
29. The effect of chemotherapy on the in vivo frequency of glycophorin A ‘null’ variant erythrocytes
30. The heritable translocation assay: its relationship to assessment of genetic risk for future generations
31. Cytogenetic effects of cyclophosphamide on human lymphocytes in vivo and in vitro
32. Aryl hydrocarbon hydroxylase in human leukocytes
33. Nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites
34. Transplacental genetic and cytogenetic effects of alkylating agents in the mouse. II. Induction of chromosomal aberrations
35. Development of an intact hepatocyte activation system for routine use with the mouse lymphoma assay
36. Activation of cyclophosphamide in man and animals
37. 766. The alkylation of guanosine and guanylic acid
38. 3-Methylcholanthrene induces monooxygenase (O-deethylation) activity of human lymphocytes
39. Translocations the predominant cause of total sterility in sons of mice treated with mutagens
40. Chemotherapy of neoplastic diseases
41. Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention
42. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes
43. Micronuclei assay in cytokinesis-blocked binucleated and conventional mononucleated methods in human peripheral lymphocytes
44. Analysis and excision of ring-opened phosphoramide mustarddeoxyguanine adducts in DNA
45. The role of individual cytochromes P450 in drug metabolism and clinical response
46. Cytogenetic effects of diethylstilbestrol-diphosphate (Des-dp) on mouse bone marrow monitored by the micronucleus test
47. Micronuclei in bone-marrow cells of mice subjected to hyperthermia
48. Kinetics of spermatogenesis in mammals: seminiferous epithelium cycle and spermatogonial renewal
49. Short-term tests for transplacentally active carcinogens. A comparison of sister-chromatid exchange and the micronucleus test in mouse foetal liver crythroblasts
50. 6-methylguanine in DNA from human tissues
51. Cyclophosphamide cystitis — identification of acrolein as the causative agent
52. Effect of short-term cyclophosphamide administration on rabbit sperm
53. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells
54. Genetic effects of cyclophosphamide in the germ cells of male mice
55. Temporary effects of AMSA (4′-(9-acridinylamino) methanesulfon-m-anisidide chemotherapy on spermatogenesis
56. Metabolic activation of chemicals to mutagenic carcinogens by human hepatoma microsomal extracts in Chinese hamster ovary cells (in vitro)
57. The effect of chemical mutagens on the mitotic chromosomes of the mouse, in vivo
58. Mutagenicity of selected chemicals in the mammalian dominant lethal assay
59. Evaluation of a human hepatoma cell line as a target cell in genetic toxicology
60. In vitro assays of in vivo exposure to cyclophosphamide: Induction of sister-chromatid exchanges in peripheral lymphocytes, bone-marrow cells and in cultured cells exposed to plasma
61. Mutagenicity tests with nickel salts in the male mouse
62. Influence of various mitogens on the yield of sister-chromatid exchanges, induced by chemicals, in human lymphocytes
63. Special committee report, Part I: An evaluation of current testing approaches for the detection of chemically induced aneuploidy
64. Decreased half-life of cyclophosphamide in patients under continual treatment
65. Cyclophosphamide-induced chromosomal aberrations in nontumorous patients
66. Genetically engineered V79 Chinese hamster cells metabolically activate the cytostatic drugs cyclophosphamide and ifosfamide
67. Biliary elimination of cyclophosphamide in man
68. Cyclophosphamide induced SCEs in rabbit lymphocytes
69. Investigations into sister chromatid exchanges in patients under cytostatic therapy
70. A limited sampling strategy for cyclophosphamide pharmacokinetics
71. Risk estimations based on germ-cell mutations in mice
72. Induction of specific-locus and dominant-lethal mutations by cyclophosphamide and combined cyclophosphamide-radiation treatments
73. Dominant cataract mutations and specific locus mutations in mice induced by radiation or ethylnitrosourea
74. Inhibition of post-implantation development of mouse blastocysts in vitro after cyclophosphamide treatments in vivo
75. Biochemical prophage inducation assay: a rapid test for antitumor agents that interact with DNA
76. Detection of chemical mutagens by the dominant lethal assay in the mouse
77. Pharmacology of anticancer drugs
78. Acute myelocytic leukemia after the use of cyclophosphamide in the treatment of polyarteritis nodosa
79. Postmeiotic cell mediation of behaviour in progeny of male rats treated with cyclophosphamide
80. The mammalian spot test (Fellfleckentest) with mice
81. The incidence of bladder cancer after cyclophosphamide therapy
82. Enantiomers of cyclophosphamide amd iphosphamide
83. Tumours and malformations in the adult offspring of cyclophosphamide-treated and control male rats — Preliminary communication
84. Embryolethality in the mouse following treatment of males with cyclophosphamide at specific germ cell stages
85. Sister chromatid exchanges induced by cyclophosphamide in V79 cells cultured in difusion chambers in mice
86. Modifications in the myeloclastogenic effect of benzene in mice with toluene, phenobarbital, 3-methylcholanthrene, Aroclor 1254 and SKF-525A
87. Development of a standard protocol for in vitro cytogenetic testing with Chinese hamster ovary cells: comparison of results for 22 compounds in two laboratories
88. Assessment of carcinogen exposure in man
89. The action of anticlastogens in human lymphocyte cultures and their modification by rat-liver S9 mix
90. Inducibility by chemical mutagens of heritable translocations in male and female germ cells of mice
91. Mutagenicity of selected chemicals in mammals: the heritable translocation test
92. Developmental anomalies: Mutational consequences of mouse zygote exposure
93. Modulation of cyclophosphamide mutagenicity by vitamin C in the in vivo rodent micronucleus assay
94. Acute non-lymphocytic leukaemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis
95. Relationship between experimental results in mammals and man. I. Cytogenetic analysis of bone marrow injury induced by a single dose of CO
96. Cyclophosphamide-induced chromosomal aberrations in meiotic cells of male mice
97. Comparison of the effects of 1,2-dimethylhydrazine and cyclophosphamide on micronucleus incidence in bone marrow and colon
98. Thirty compounds tested in the Drosophila wing spot test
99. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration
100. Drug metabolism in carcinogenesis and cancer chemotherapy
101. Phenotypically deficient elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients
102. Reversibility of the effects of chronic paternal exposure to cyclophosphamide on pregnancy outcome in rats
103. 2 progeny of male rats chronically treated with cyclophosphamide
104. The action of cytostatic agents on the chromosomes of human leukocytes in vitro
105. Chromosome aberrations in metaphase II oocytes: Stage sensitivity in the mouse oogenesis to amethopterin and cyclophosphamide
106. Future directions in the use of DNA adducts as dosimeters for monitoring human exposure to environmental mutagens and carcinogens
107. Induction of micronuclei in the mouse, Revised timing of the final stage of erythropoiesis
108. Comparative mutagenicity of myleran and cyclophosphamide
109. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice
110. Screening of carcinogens with the prophage lambdaclts857 induction test
111. The problem of oncostatic specificity of cyclophosphamide
112. Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis
113. An in vitro metabolic activation assay using liver microsomes in diffusion chambers: induction of sister chromatid exchanges and chromosome aberrations by cyclophosphamide or ifosfamide in cultured human and Chinese hamster cells
114. Radiation-induced heritable sperm abnormalities in mice
115. Rapid detection of mutagen induced micronucleated erythrocytes by flow cytometry
116. Analysis of HPRT-deficient lymphocytes in mouse (spleen) and man (peripheral blood)
117. Differential inducibility of chromosome aberrations and sister-chromatid exchanges by indirect mutagens in various mammalian cell lines
118. Induction of sister chromatid exchanges by cyclophosphamide in human lymphocytes with metabolic activation.
119. Effect of cyclophosphamide in rams
120. 131I and of two cytostatics revealed by the micronucleus test (MT)
121. Morphological and cytogenetic studies of dominant lethality induced by mitomycin C and cyclophosphamide in female germ cells
122. Analysis of results from a collaborative study of the dominant lethal assay
123. Phenobarbital effects on cyclophosphamide pharmacokinetics in man
124. Malformed foetuses and karyotype abnormalities in the offspring of cyclophosphamide and allyl alcohol-treated male rats
125. Increased incidence of abnormal foetuses in the offspring of cyclophosphamide-treated male mice
126. Electrophoretically detected germinal mutations induced in the mouse by ethylnitrosourea
127. Factors that affect the frequency of thioguanine-resistant lymphocytes in mice following exposure to ethylnitrosoures
128. First pass hepatic metabolism of cyclophosphamide
129. Alkylation of guanosine by phosphoramide mustard, chloromethane hydrochloride and chlorambucil
130. Transplacental mutagenesis: The micronucleus test on fetal mouse blood
131. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment
132. The mammalian spot test and its use for the testing of potential carcinogenicity of welding fume particles and hexavalent chromium
133. A proposed method for the simultaneous detection of germ-cell mutations leading to fetal death (dominant lethality) and of malformations (male teratogenicity) in mammals
134. Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector
135. Chromosomal analysis in bone-marrow cells of Chinese hamsters after treatment with mycotoxins
136. Cyclophosphamide-induced cytogenetic effects in mouse bone marrow and spleen cells in in vivo and in vivo/in vitro assays
137. Use of the cytokinesis-block method for the analysis of micronuclei in V79 Chinese hamster lung cells: results with mitomycin C and cyclophosphamide
138. Simultaneous micronucleus and chromosome aberration assessment in the rat
139. The effectiveness of S9 and microsomal mix on activation of cyclophosphamide to induce genotoxicity in human lymphocytes
140. Micronuclei induced during meiosis by ethyl methanesulfonate, cyclophosphamide and dimethylbenzanthracene in male rats
141. Induction and survival of micronuclei in rat spermatids. Comparison of two meiotic micronucleus techniques using cyclophosphamide
142. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo
143. Interaction of anti-cancer drugs with hepatic monooxygenase enzymes
144. Comparison of three short-term assays: results on seven chemicals, potential contribution to the control of water genotoxicity
145. Observation of dividing spermatocytes for chromosome aberrations induced in mouse spermatologonia by chemical mutagens
146. Cytotoxicologie. Comparaison, in vivo, des propriétés clastogéniques du busulfan et du cyclophosphamide
147. Chemical probes and possible targets for the induction of aneuploidy
148. Mutagenesis by apurinic/apyrimidinic sites
149. A cyclophosphamide-DNA phosphoester adduct formed in vitro and in vivo
150. Clastogen-induced micronuclei in peripheral bood erythrocytes: The basis of an improved micronucleus test
151. Experiences with the dominant lethal test in female mice: Effects of alkylating agents and artificial sweeteners on pre-ovulatory oocyte stages
152. Method for testing mutagenic effects of chemicals on spermatogonia of the Chinese hamster
153. Evaluation of the mutagenic potential of cyclohexylamine on spermatogonia of the Chinese hamster
154. Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems
155. Evaluation of experimental parameters in an S9/human leukocyte SCE test with cyclophosphamide
156. In vitro testing of indirect mutagen (CP) with human leukocytes culture. Activation with liver microsomes and use of dialysis bag
157. In vitro testing of an indirect mutagen (cyclophosphamide) with human leukocyte cultures. Activation by a non-enzymatic hydroxylation system (Udenfriend system)
158. Testing in vitro of an indirect mutagen (cyclophosphamide) with human leukocyte cultures Activation by liver perfusion and by incubation with crude liver homogenate
159. Ten model mutagens evaluated by the micronucleus test
160. The Escherichia coli K-12 SOS chromotest agar spot test for simple, rapid detection of genotoxic agents
161. Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450
162. Measurement of ‘unscheduled’ DNA synthesis in HeLa cells by liquid scintillation counting after carcinogen treatment
163. Testing of known carcinogens and noncarcinogens for their ability to induce unscheduled DNA synthesis in HeLa cells
164. Cytochrome P-450 and chromosome damage by cyclophosphamide in LEC strain rats predisposed to hereditary hepatitis and liver cancer
165. Influence of cytostatic therapy on andrologic findings
166. Baseline and phosphoramide mustard-induced sister-chromatid exchanges in cancer patients treated with cyclophosphamide
167. Baseline and phosphoramide mustard-induced sister-chromatid exchanges in pharmacists handling anti-cancer drugs
168. Trapping of DNA-reactive metabolites of therapeutic or carcinogenic agents by carbon-14-labelled synthetic polynucleotides
169. Alkylation of guanosine and deoxyguanosine by phosphoramide mustard
170. The human lymphocyte micronucleus assay: a comparison between whole-blood and separated-lymphocyte cultures
171. Differential chromosomal damage in Chinese hamster bone-marrow cells and in spermatogonia after mutagenic treatment
172. Identification of cyclophosphamide-DNA adducts in rat embryos in vitro to 4-hydroxyperoxy-cyclophosphamide
173. Analysis of in vivo results of cyclophosphamide-induced chromosomal damage in mammals from sensitivity and statistical aspects
174. Genetic effects of cyclophosphamide, ifosfamide and trofosfamide
175. Mutagenicity of methyl methanesulfonate and cyclophosphamide in resting and growing Saccharomyces cerevisiae D7 cells
176. Clinical pharmacokinetics of cyclophosphamide
177. Non-random distribution of cyclophosphamide-induced chromosome breaks
178. Effects of prolonged chemical treatment with cyclophosphamide and 6-mercaptopurine in the dominant lethal test system
179. The synaptonemal complex in meiosis: Significance of induced perturbations
180. Effect of ‘pan masala’ on the germ cells of male mice
181. Genetic counseling of the cancer patient
182. Offspring of long-time survivors of childhood cancer
183. Sister-chromatid exchanges and chromosal breakage in patients treated with cytostatics
184. ™ Mouse: a transgenic mouse model for detecting mutations in vivo
185. Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives
186. In vivo cytogenetic studies of 10-chloro-11b-(2-fluorophenyl)-7-(2-hydroxyethyl)-2,3,5,11b-tetrahydrooxazolo-[3,2-d] [1,4] benzodiazepine-6(7H)-one (MS-4101) on rat bone marrow cells
187. Effect of chemotherapy on the lymph node and bone marrow cell chromosomes in patients with Hodgkin's disease
188. Mutagenesis assays on urines produced by patients administered adriamycin and cyclophosphamide
189. Exposure of pharmacy personnel to mutagenic antineoplastic drugs
190. Metabolic activation of styrene by erythrocytes detected as increased sister chromatid exchanges in cultured human lymphocytes
191. Germ cell toxicity: significance in genetic and fertility effects of radiation and chemicals
192. Modulation of the control of mutagenic metabolites derived from cyclophosphamide and ifosfamide by stimulation of protein kinase A
193. Induced hepatocytes as a metabolic activation system for the mouse-lymphoma assay
194. Bladder cancer after cyclophosphamide therapy for lupus nephritis
195. Susceptibility to genotoxic effects of niclosamide in human peripheral lymphocytes exposed in vitro and in vivo
196. Cytogenetic observations in mouse secondary spermatocytes on numerical and structural chromosome aberrations induced by cyclophosphamide in various stages of spermatogenesis
197. Genetic effects of pesticides in the mammalian cells. I. Induction of micronucleus
198. Metabolism and pulmonary toxicity of cyclophosphamide
199. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma
200. Inducibility of somatic colour and white spots in the mammalian spot test
201. Comparative efficacy of different tests for determining the mutagenicity of certain factors in mammals, II. Frequency of abnormal sperm heads in mice exposed to various factors
202. Adverse effects of cyclophosphamide on progeny outcome can be mediated through post-testicular mechanisms in the rat
203. 32P-post-labeling test for DNA damage
204. Sister chromatid exchange studies for monitoring DNA damage and repair capacity after cytostatics in vitro and in lymphocytes of leukaemic patients under cytostatic therapy
205. SCE induction by cytostatics and its relation to iatrogenic leukemogenesis
206. Cytogenetic effects of cyclophosphamide on mouse spermatogonia
207. Comparative cytogenetic studies of the influence of phenylbutazone and cyclophosphamide on spermatogenesis in the mouse
208. Quantitative estimation of the genetic risk associated with the induction of heritable translocations at low-dose exposure: ethylene oxide as an example
209. An assessment of the clastogenic potential of 4-chloromethylbiphenyl in human lymphocytes in vitro
210. The dominant lethal effects of some ergot alkaloids
211. The activity of alkylating agents: I. Sensitive mutable stages in spermatogenesis and oogenesis
212. Induced chromosome aberrations in unfertilized oocytes of mice
213. Investigations on the frequency of chromosome aberrations in bone marrow cells of Chinese hamsters after simultaneous application of caffeine and cyclophosphamide
214. Cytogenetic investigations of mammals, comparison of the genetic activity of cytostatics in mammals
215. Genotoxicity, metabolism and blood kinetics of epichlorohydrin in mice
216. Effects of various cyclophosphamide concentrations in vivo on sister chromatid exchanges (SCE) and chromosome aberrations of Chinese hamster bone marrow cells
217. The mouse specific-locus test with agents other than radiations: interpretations of data and recommendations for future work
218. Factors affecting the nature of induced mutations
219. Developmental anomalies derived from exposure of zygotes and first-cleavage embryos to mutagens
220. Mutagenic activity of 41 compounds in the in vivo micronucleus assay
221. On the complexities of risk estimates, metabolic activation, and chemical mixtures
222. The protective effect of β-carotene on genotoxicity induced by cyclophosphamide
223. Application of new techniques for the detection of carcinogen adducts to human population
224. Human lymphocytes assay: Cyclophosphamide metabolic activation by S9 system with low cytotoxicity
225. A rapid screen for cumulative chromosomal damage in mice accumulation of circulating micronucleated erythrocytes
226. Unscheduled DNA synthesis in male rabbit germ cells induced by methylmethane sulfonate, cyclophosphamide and adriamycin
227. Chemical mutagenesis, The Chinese hamster bone marrow as an in vivo test system, I. Cytogenetic results on basic aspects of the methodology, obtained with alkylating agents
228. Chromosome mutations and chromosome stability in children treated with different regimes of immunosuppressive drugs
229. The role of dominant visibles in mutagenicity testing
230. The importance of the direct method of genetic risk estimation and ways to improve it
231. Non breeding-test methods for dominant skeletal mutations shown by ethylnitrosourea to be easily applicable to offspring examined in specific locus tests experiments
232. Effect of mitomycin-C and cyclophosphamide on the polytene chromosomes of Anopheles stephensi (Culicidae: Diptera)
233. The feasibility of using Chinese hamsters as an animal model for aneuploidy
234. The micronucleus test with mouse spleen cells
235. Carcinoma of bladder following long-term cyclophosphamide therapy
236. Species differences in the genotoxicity of cyclophosphamide and styrene in three in vivo assays
237. Alkaline elution of rat testicular DNA: Detection of DNA cross-links after in vivo treatment with chemical mutagens
238. Unscheduled DNA synthesis detection and metaphase analysis in a common test system in vivo-in vitro
239. Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity
240. Some problems associated with the testing for environmental mutagens and a perspective for studies in comparative mutagenesis
241. The parallelogram: An indirect approach for the assessment of genetic risks from chemical mutagens
242. Induction of sister chromatid exchanges among nurses handling cytostatic drugs
243. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals
244. Induction of translocations by cyclophosphamide in different germ cell stages of male mice: Cytological characterization and transmission
245. Unscheduled DNA synthesis in spermatogenic cells of mice treated in vivo with the indirect alkylating agents cyclophosphamide and mitomen
246. In vitro assesment of pharmacogenetic susceptibility to toxic drug metabolites in human
247. Relationship between acute and chronic exposures in mutagenicity studies in mice
248. Change in the frequency of chromosome aberrations in the bone marrow of mice examined at various intervals after a single dose or continuous exposure to cyclophosphamide
249. Lack of mutagenic activity in urine from hospital pharmacists admixing antitumor drugs
250. Testing in vitro of an indirect mutagen (cyclophosphamide) with human leukocyte cultures: Activation by liver perfusion and by incubation with crude liver homogenate
251. Sister chromatid exchange as an assay for genetic damage induced by mutagencarcinogens. I. In vivo test for compounds requiring metabolic activation
252. Sister chromatid exchange as an assay for genetic damage induced by mutagencarcinogens, II. In vitro test for compounds requiring metabolic activation
253. A comparison of the incidence of micronuclei in blood and bone marrow in 3 strain of mouse dosed with cyclophosphamide or hexamethylphosphoramide (HMPA)
254. Dominant-lethal assay of selected cytostatics
255. Experiences with methods testing the mutagenic and antifertility effects of the model drug cyclophosphamide
256. Pharmacokinetics and metabolism of cyclophosphamide in paedriatic patients
257. Validation studies with the micronucleus test for early spermatids of rats. A tool for detecting clastogenicity of chemicals in differentiating spermatogonia and spermatocytes
258. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis
259. Sperm shape abnormalities in the offspring of male mice treated with triethylenemelamine (TEM)
260. Chemically induced transmissible abnormalities in sperm-head shape
261. The detection of carcinogen-induced sperm head abnormalities in mice
262. Cytogenetic examination of bone marrow cells and peripheral lymphocytes in rats exposed to cyclophosphamide
263. Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility
264. Bladder cancer after chemotherapy for non-Hodgkin's lymphoma
265. A sensitive method to measure ‘unscheduled DNA synthesis’ in rapidly dividing eukaryotic cells
266. Activity of coded compounds in the micronucleus test
267. Sister-chromatid exchange: second report of the Gene-Tox program
268. Annex G. Hereditary effects of radiation
269. Mutagenicity tests with astemizole in vitro and in vivo
270. Induction of SOS response in Escherichia coli strain PQ37 by 16 chemical compounds and human urine extracts
271. Alkylating agents and mouse spermatogenesis: Effects of a single dose of cyclophosphamide
272. 1 and N-methyl-N-nitrosourea
273. Performance of 181 chemicals in a Drosophila assay predominantly monitoring interchromosomal mitotic recombination
274. Comparative studies of three mutagenicity carcinogenicity tests using cyclophosphamide and benzo[a]pyrene
275. Evaluation of the SOS chromotest
276. Identification of three alkylated nucleotide adducts from the reaction of guanosine-5′-monophosphate with phosphoramide mustard
277. Sister-chromatid exchanges induced in vitro by cyclophosphamide without exogenous metabolic activation in lymphocytes from three mammalian species
278. Interactions of Anti-Cancer Drugs with Cytochromes P450 and Glutatione S-Transferases: Drug Activation and Drug Resistance Mechanisms
279. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes
280. A method utilizing human lymphocytes with in vitro metabolic activation for assessing chemical mutagenicity by SCE analysis
281. Cytogenetic effects in the mouse of 17 chemical mutagens and carcinogens evaluated by the micronucleus test
282. Sister chromatid exchange induction in mouse B- and T- lymphocytes exposed to cyclophosphamide in vitro and in vivo
283. Chemical induction of sperm abnormalities in mice
284. An evaluation of the mouse sperm morphology test and other sperm tests in nonhuman mammals: A report of the US Environmental Protection Agency Gene-Tox Program
285. In vivo study on the frequency of sister chromatid exchange (SCE) and micronuclei (MN) induced by cyclophosphamide in bone marrow and spleen cells in rodents
286. Additional data in support of the quadruplicated white-ivory reversion system to test for somatic genotoxicity in Drosophila melanogaster
287. Transplacental genotoxicity of triethylenemelamine, benzene, and vinblastine in mice
288. A comparison of diameters of micronuclei induced by clastogens and by spindle poisons
289. Studies on micronuclei time response and on the effects of multiple treatments of mutagens on induction of micronuclei
290. Aneuploidy determination in C-banded mouse metaphase II oocytes following cyclophosphamide treatment in vivo
291. Assessment of male reproductive toxicity: A risk assessment approach
292. Dynamics of dominant lethal mutations in male mice exposed for different periods to cyclophosphamide in drinking water
293. Effects of long-wave ultraviolet radiation on the frequency of chromosome aberrations induced by cyclophosphamide in mouse bone marrow cells
294. The ratio of induced recessive lethals to ring-x loss has prognostic value in terms of functionality of chemical mutagens in Drosophila melanogaster
295. Cyclophosphamide-induced spermatogenic effects detected in the F1 generation by behavioral testing
296. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
297. Use of an established human hepatoma cell line with endogenous bioactivation for gene mutation studies
298. Acrosomal proteolytic assay for detection of mutagens in mammals
299. Untersuchungen am Samenepithel der Ratte nach Gaben von Endoxan und Natulan
300. Chromosomal aberration test on 29 chemicals combined with S9 mix in vitro
301. Exposure of hospital pharmacists and nurses to antineoplastic agents
302. Die Induktion von chromosomenaberrationen durch Mitomen und Endoxan bei Vicia faba und der Transportform-Wirkform-Mechanismus
303. The cofactor effect: variocele and infertility
304. Über den Einfluss von Trenimon und Endoxan auf die Meiose der männlichen Maus: II Cytogenetische befunde nach behandlung mit trenimon und Endoxan
305. The activity of alkylating agents, II. Histological and cytogenetic findings in spermatogenesis
306. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies
307. Occupational exposure to anticancer drugs — Potential and real hazards
308. Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny